CSU I-CorpsTM Evaluators and Experts

CSU I-Corps Teams are evaluated by panels drawn from the CSU I-Corps’ network of industry association partners, alumni, life science industry professionals, and experienced entrepreneurs. CSUPERB recruits tailored panels based on the expertise needed to evaluate each cohort of teams. Panels review the teams’ presentations to assess the problem-solution fit, product maturity and teamwork. Panels can give special recognition to teams who demonstrate significant learning and/or who identify a compelling entrepreneurial opportunity.  As our expert network becomes familiar with the CSU I-Corps program, some evaluators opt in and join the teaching team as guest instructors, workshop designers and office hour consultants.


Mark Adams, PE, is President of NorthStar Engineering located in Chico, CA, and is responsible for the day-to-day operations as well as planning the future of the growing company. He has over 35 years of civil engineering experience covering a broad range of subjects, specializing in the design of decentralized wastewater collection, treatment, dispersal, and reuse systems. He is experienced in designing systems for projects where other systems have previously failed or where site conditions are limiting. He is currently President of the California On-Site Water Association, Chairman of the Professional Advisory Board, Department of Civil Engineering, CSU Chico, and a member of the new Decentralized Water Reuse Policy Council, Black Water Working Group. (Evaluator, Cohort #1, Fall 2014)

Stephen Betz is Vice President of Biology and a co-founder of Crinetics Pharmaceuticals. He earned his Ph.D. in Chemistry from the University of North Carolina at Chapel Hill where he studied protein structure and stability. He pursued postdoctoral studies in the laboratory of William DeGrado at the DuPont Merck Pharmaceutical Company where he focused on protein engineering and de novo design. He moved to pharmaceutical discovery in the Research NMR Group at Abbott Laboratories, working on protein structure, structure-guided drug design, assay development, and compound screening in several different therapeutic areas. Subsequently, he led laboratory efforts at GeneFormatics, a biotechnology company founded on protein function annotation and characterization. Most recently, he was Director of Endocrinology and Metabolism at Neurocrine Biosciences working on the discovery and development of GnRH receptor antagonists and nonpeptide modulators of other endocrine targets. (Teaching Team, Cohort #2, Spring 2015)

Meredith Brown is Director of Business Development, Cell Therapy for Invetech. Prior to joining Invetech, she was CEO and president of two biotech companies. Meredith also worked for a venture capital office and consulted in the areas of corporate strategy development, industry research, business investment, and science and technology evaluation. She received her MBA from University of Texas, Austin and her BA in Biological Sciences from University of California, Santa Barbara. She has also volunteered as a judge for the Rice Business Plan Competition and the Texas Emerging Technology Fund and now sits on several Alliance for Regenerative Medicine committees. (Evaluator, Cohort #4, Spring 2016)

Elise Brownell, PhD. has spent the last 35 years in the bio/pharmaceutical arena where she has played key roles in Discovery, Development and Opportunity Assessment to drive innovation. After completing her doctorate, Elise’s career started at SUNY Stony Brook where she made discoveries relating to genetic evolution in the great apes. She continued her interest in comparative molecular biology during her tenure at Frederick Cancer Research Facility and expanded her facility with molecular genetics while in various functions at Bayer Healthcare. As Director, Project Management, she led global cross-functional teams to bring several of Bayer’s biopharmaceuticals from bench to clinic. She was a member of the founding team of a venture-backed spin out (Aerovance, Inc), where she became head of project management. During her tenure as Senior Director, Aerovance garnered over $ 60 MUSD, completed six clinical trials in 3.5 years, and built a right-sized matrixed organization. In 2008, she co-founded ZephyrBiotech, LLC, a consulting practice that provides project leadership, management and planning to entrepreneurial life science companies, especially those that are early-stage, venture-backed entities. Her experience within the investment community has been strengthened by her tenure with The Angels’ Forum (2012-2014), where she was responsible for managing all incoming deal flow and presentation preparation. Currently, Dr. Brownell serves as Executive Vice President of Operations and Project Management at Amarantus Bioscience Holdings, Inc. where she oversees all development programs across a diverse therapeutics portfolio. She is a highly regarded mentor/advisor for entrepreneurial programs conducted through Astia, UC Berkeley BPlan and the NCI/SBIR Investor Forum. (Evaluator, Cohort #5, Fall 2016)

Karen J. L. Burg earned a bachelor’s degree in chemical engineering from North Carolina State University, a master’s and doctorate in bioengineering from Clemson University, and a postdoctorate at Carolinas Medical Center. Honors to Dr. Burg include a Presidential Early Career Award for Scientists and Engineers, recognition as a Massachusetts Institute of Technology’s TR100 Young Innovator, an American Institute for Medical and Biological Engineering Fellow, and designation as an American Association for the Advancement of Science-Lemelson Invention Ambassador. Four Burg patents served as the basis for a diagnostics startup company and a global business competition. (Evaluator, Cohort #1, Fall 2014)

Anna Christensen, PhD is the CEO and Co-founder of Magnetic Insight Inc.  Previously Dr. Christensen led the in vivo imaging business for PerkinElmer Inc. as the global business leader and prior to the acquisition she managed the in vivo imaging business at Caliper Life Sciences for over 6 years. She also held senior management positions at DiscoverX and Molecular Devices and has advanced degrees in cell biology and neurobiology from UC San Diego and Copenhagen University. (Evaluator, Cohort #1, Fall 2014)

Jim Cooper is a consultant (Conscientia Research; Entrepreneur-in-Residence, PortTechLA) who works with very early stage companies on planning for proof-of-concept and pre-revenue milestones. He is an expert in lean startup and commercialization strategies. He specializes in new and emerging technologies, market and customer validation and competitive analysis. He assists companies with SBIR proposal development, particularly in life sciences, computer tech and automation, agtech and cleantech. (Evaluator, Cohort #1, Fall 2014 & Cohort #3, Fall 2015)

Ina Deras has a BS in chemistry from Willamette University and a PhD in bioorganic chemistry from Purdue University. She has held positions at Roche Diagnostics, Gen-Probe (now Hologic), and Invivoscribe, and is currently a Staff Scientist at Illumina. She has executed all phases of in vitro diagnostic (IVD) product development at multiple levels of US and international regulatory approvals, with a focus on oncology (prostate, leukemia, and universal panel). (Evaluator, Cohort #2, Spring 2015)

Neelima Firth is a biopharmaceutical executive with reimbursement, marketing and international experience in startup and Fortune 500 biopharmaceutical companies including Amgen and the Alfred Mann Foundation. As the Senior Director for Strategic Planning at AMF, Neelima was responsible for strategic planning, business development and market research. The Foundation has spun out two companies and Neelima was intimately involved in the business planning, financial analysis and successful spin outs of these companies. She was instrumental in building the initial UK presence of Amgen. Neelima held responsibility for Medicare & Medicaid marketing and was a key team member in corporate reimbursement strategy. She led the strategic planning and operations group and managed the brand plan across the alliance partnership. (Evaluator, Cohort #3, Fall 2015)

Bruce Fleming manages the Augmentative and Alternative Communication (AAC) program at the San Diego Assistive Technology Center, a division of United Cerebral Palsy. He holds a BS in Mechanical Engineering from Santa Clara University, and certificates in Rehabilitation Engineering Technology and Technical Communications from San Francisco State University. He has spent the past 25 years in Assistive Technology (AT) R&D, clinical applications, and marketing and sales, in a variety of settings. He has extensive experience in the legislation, funding, and provision of AT in education and healthcare, as well as the integration of computers, AAC, and powered mobility. (Evaluator, Cohort #2, Spring 2015)

Daniel Forer (Aquantia Corp.) is a Silicon Valley native with over five years of technical experience as a systems engineer for telecommunication and semiconductor start-ups in the San Francisco Bay Area. Daniel received his B.S. in Electrical Engineering with a focus in wireless communication and bio-medical signal analysis from CSU Sacramento. He has been involved in developing cutting edge technologies such as non-line-of-sight solutions for wireless fiber extensions and fixed wireless access. Daniel currently works on high-speed connectivity solutions for data centers, enterprise and WLAN applications. His professional work includes system verification and integration, digital signal processing, firmware development and testing automation. (Evaluator, Cohort #3, Fall 2015)

Gary Fujii is President and CEO of Molecular GPS Technologies, a holding company that manages several subsidiary companies: Molecular Express, BioCerax and Clayton Chemical. Dr. Fujii has focused much of his career on coupling scientific and technological expertise with business experience in an entrepreneurial environment to facilitate the translation of scientific discoveries from academia into the commercial sector. Dr. Fujii serves as a reviewer for numerous scientific journals and is a member of the editorial board of Pharmaceutical Research. He also serves as a regular member of the Vaccines Against Microbial Diseases study section for the National Institute of Allergy and Infectious Diseases. Dr. Fujii is a member of the Board of Directors of the Southern California Biomedical Council, a non-profit organization devoted to promoting the development of the biomedical industry in the Greater Los Angeles Area. Dr. Fujii obtained B.S. degrees in the Biological Sciences and Physical Sciences from the University of California Irvine and a Ph.D. from the University of California Los Angeles. (Evaluator, Cohort #2, Spring 2015)

David Heckadon is Of Counsel in Gordon & Rees’s San Francisco office and a member of the Intellectual Property practice group. Mr. Heckadon’s Intellectual Property practice focuses on patent application and prosecution. He has significant experience managing corporate patent portfolios and dockets (both domestic and foreign), and managing the patenting process from reviewing initial invention disclosure forms and meeting with inventors to drafting and prosecuting patents to allowance. Mr. Heckadon also has significant experience with freedom to operate and infringement analyses, due diligence reviews and patent technical review for litigation support. Mr. Heckadon’s patent practice spans a wide variety of technical fields, including: (a) electro-mechanical systems, mechanical systems, scanning devices, medical imaging; (b) internet and computer systems, software and business method patents, pharmaceutical software management systems, (c) chemical analysis systems, renewable energy, microfluidics, (d) medical device systems, and (e) design patents. A registered patent attorney, Mr. Heckadon also handles matters covering trademarks, copyrights, trade dress, trade secrets, licensing, technology transfer, and non-disclosure and non-compete agreements in global markets. Mr. Heckadon’s Green Technology practice focuses on patent applications for renewable energy companies, Green Building issues and greenhouse gas legislation. Mr. Heckadon is the first and only lawyer in the U.S. who is both a registered U.S. Patent Attorney and a Leadership in Energy & Environmental Design Accredited Professional (LEED® AP) certified by the U.S. Green Building Council. (Evaluator, Cohort #5, Fall 2016)

Dennis Hester, Ph.D. was appointed Vice President, Product Development and Head of CMC at Mirati Therapeutics, Inc. in July 2014 after building a CMC team and serving as Executive Director, Product Development and Head of CMC from September 2013. Dr. Hester has over twenty years of experience in the development of large and small molecules working with a number of development platforms including solid/liquid oral, inhalation and parenteral technologies. Most recently, he served as Senior Director, Pharmaceutical Sciences at Aragon Pharmaceuticals working on ARN-509, for prostate cancer, which was acquired by Johnson & Johnson in July of 2013 and ARN-810, for Breast Cancer, with was acquired by Genentech in July 2014. Prior to Aragon, Dr. Hester was Director, Pharmaceutical Development at Intellikine working on kinase inhibitors INK-128 and INK-1117 that were acquired by Takeda in January 2012. From March 2003 to October 2006, Dr. Hester was Associate Director, Product Development at Amylin Pharmaceuticals. Prior to Amylin he was a CMC Lead working on inhalation technologies for various therapeutic indications at Nektar Therapeutics (formerly Inhale Therapeutics). Dr. Hester holds a Ph.D. in Physical Chemistry from the University of Southern California, an ACS Accredited B.S. in Chemistry from the United States Air Force Academy and is an inventor on six U.S. patents. (Evaluator, Cohort #4, Spring 2016)

Steve Karp’s career has spanned the gamut of operations in small life science companies. Early on he ran manufacturing facilities producing medical devices and then moved into product development and alliance management. For the last fifteen years he has managed operations developing and commercializing a variety of biologicals, small molecules and large, as well as a stint in the world of synthetic biology. Currently, he runs an advisory program for life science startups, the Fellows All-Star Team (FAST) Advisory program, at BayBio, Northern California’s Life Science Association. (Evaluator, Cohorts #1 & 3, Fall 2014 & Fall 2015)

Taylor Lane completed her Bachelors of Science in Biology at UC Santa Barbara, where she worked as a veterinary assistant for 4 years. She received her Masters in Biology with an emphasis in Microbiology at Cal Poly Pomona. As a graduate student at CPP, she participated in the 2014 CSU I-CorpsTM and developed Poly Probiotic, a novel vaginal probiotic distribution mechanism. Currently, she works at Ritual Brewing Company assisting in Quality Control and developing Standard Operating Procedures for the brewery.  (Evaluator, Cohort #3, Fall 2015)

Richard Lin is founder, president and CEO at Explora BioLabs. Richard is also very active in the San Diego biotech community; he serves on the Planning Committee of the BIOCOM CRO Initiative, the Industry Advisory Board of the Southern California Biotech Center, and is a frequent speaker at local bioentrepreneur events. Richard has more than 25 years of academic research and industry drug development experience, with extensive knowledge of cancer biology, metabolic diseases, and animal physiology. Prior to founding Explora BioLabs in 2004, Richard held leadership positions in research and preclinical development at Ansata Therapeutics, Genset Corporation, Corvas International, and Axys Pharmaceuticals. Richard conducted his postdoctoral research at UC San Diego Cancer Center, and received his PhD in Zoology from UC Berkeley. (Evaluator, Cohort #2, Spring 2015)

Tommy Martindale is currently the Interim Director of Technology Transfer at the SDSU Research Foundation. He is  responsible for the protection and commercialization of technologies developed at SDSU. He supports SDSURF by managing its portfolio of intellectual property that stems from faculty inventions, evaluating the market potential for those inventions, and commercializing SDSURF’s technologies through licensing. Since joining SDSURF, Tommy has helped foster growth of the TTO’s income from $373,030 in FY 2011-12 to $1,426,063 in FY 2013-2014. Tommy is a patent attorney and gained experience with the Corporate Legal Department at Qualcomm, Inc. and the Intellectual Property Group at Higgs, Fletcher & Mack, LLP before joining SDSURF. (Evaluator, Cohort #1, Fall 2014; Teaching Team, Cohort #2, Spring 2015; Teaching Team, Cohort #4, Spring 2016)

Nola Masterson is Managing Director of Science Futures Management Company, LLC., a 30 year old investment and advisory firm. Ms. Masterson is a biotechnology industry leader and forward thinker with more than 35 years of business experience in the life sciences industry and in venture capital investment. From 2000 to 2005, she was a Venture Partner with TVM Capital GmbH, one of the first and largest venture capital firms in Germany. She sourced and invested in three companies and built out their San Francisco office. She was a co-founder and President of Sequenom, Inc., a DNA sequencing company which went public on Nasdaq in 2000, and wrote the first business plans for IDEC and Insight Vision, as a consultant to Kleiner Perkins Caufield & Byers, and for ReSound, with Dr. Rodney Perkins, the founder. She was the first biotech analyst on Wall Street for Drexel Burnham and Merrill Lynch. Ms. Masterson is Chairwoman of the Board of Directors of Repros Therapeutics Inc. (RPRX). She is Chairwoman Emeritus of the BayBio Institute, a non-profit organization serving the Northern California life sciences industry by focusing on best practices, entrepreneurship, workforce development and science education, and also serves on the Board of Advisors to Astia, a non-profit organization dedicated to advancing women entrepreneurs. A a graduate of the Stanford Law School Board of Directors College course, she is currently in her second year as an Adjuct Professor at the University of San Francisco, teaching Biotech, Local, National and International in the School of Business. In 2003, she was included in Irish America magazine’s annual “Business 100” and received the Alumni Achievement Award from Marymount College at Fordham University in 2004. Ms. Masterson is an avid horseback rider, and mother of a daughter and a step-daughter.  (Evaluator, Cohort #1, Fall 2014)

Luanne Meyer (Meyer & Associates Market Research) is currently a marketing research consultant focused on new product development and strategy for biotechnology companies; she has spent most of her career in that industry. She has extensive experience working both withinbiotechnology companies and consulting to them, and enjoys both roles. Luanne is the former Director of Strategic Initiatives at CSU East Bay’s College of Business and Economics (CBE). Her key focus there was on bringing real-world biotechnology experience, as part of STEM-infused education, to business students. She began the Business Opportunity Program for CBE, a program that introduced projects related to health care and diagnostic testing to the classroom.  (Evaluator, Cohort #1, Fall 2014; Evaluator, Cohort #3, Fall 2015; Teaching Team, Cohort #4, Spring 2016)

Sylvia Norman, Ph.D. is the founder and CEO of Sandhill Crane Diagnostics, Inc. She has extensive experience in the biotechnology industry, specializing in developing diagnostic assays and medical devices. Sylvia founded Sandhill Crane Diagnostics, Inc. to develop technology to enable delivery of affordable digital health products to rural populations. Prior to Sandhill Crane Diagnostics, she founded Molecular Diagnostics Consulting to provide efficient and affordable guidance to startup companies developing diagnostic products. Sylvia is certified in Project Management and Regulatory Affairs Essentials. She has participated in generating documentation for the WHO Prequalification of In Vitro Diagnostics Programme and is an ongoing peer reviewer for NIH grant applications. Sylvia is passionate about entrepreneurship and currently serves as a board/executive committee member for the San Diego Entrepreneurs Exchange. (Evaluator, Cohort #4, Spring 2016)

Larry Ozeran practiced trauma and general surgery for 20 years and has developed software for 30 years. He is deeply involved in national informatics policy, recently completing four years of service on Public Policy Committees for for two national associations. He has been quoted and published on topics from health technology failure to patient privacy to healthcare reform. As President of Clinical Informatics, Dr. Ozeran advises clients on public policy, strategic planning, governance, provider engagement, and clinician training. As President of Informed Health Technologies, he leads a team developing a secure, patient-centric solution to improve adherence to recommended therapy.  (Evaluator, Cohort #1, Fall 2014)

David Pauling presently holds the position of Associate General Counsel and Senior IP Counsel for Sutro Biopharma, Inc., an early-stage biopharmaceutical company focused on cell-free expression of protein pharmaceuticals. At Sutro, David is the legal department, handling all aspects of the company’s legal arrangements, including agreements, routine employment matters, and particularly the company’s IP portfolio, including patent preparation and prosecution, freedom-to-operate, IP-related agreements, trademarks, and trade secrets. Prior to joining Sutro in 2011, David practiced with Pennie and Edmonds LLP and Jones Day, focusing primarily on patent preparation and prosecution, opinion work, IP due diligence, and strategic client counseling for life science companies. David’s educational achievements include a J.D. from Santa Clara University School of Law (magna cum laude) in 2002 and a M.A. (Molecular Biology) from University of California, Santa Cruz in 1999.  (Evaluator, Cohort #1, Fall 2014)

Craig Pritsky is a veteran sales and marketing professional in the medical device space having worked in both Fortune 500 and venture capital backed startups (Stryker Orthopaedics and Invuity, Inc. respectively). With a strong understanding of sales and marketing practices necessary to introduce paradigm shifting technology to the market, Craig has earned recognition for his strong business development skills, ability to navigate the evolving healthcare economic arena and ability to grow companies regardless of the product being represented. His educational background includes studies at Stanford University and a Bachelor of Science degree in Foreign Service from Georgetown University. (Evaluator, Cohort #3, Fall 2015)

John Rodenrys is the Executive Director of R&D of Leading Ventures, Inc. and was the CEO and co-Founder of the previous company, Leading Ventures LLC, from its inception in 2005. Previously he was CEO of SafetyMate Corporation and Chief Operating Officer of ForHealth Technologies, where he was responsible for R&D, manufacturing, quality assurance, customer service and field operations. Mr. Rodenrys is an active member of the San Diego Tech Coast Angels. He holds a BS in engineering from Rensselaer Polytechnic Institute (RPI), a master’s in Management Science from US International University (USIU) and is certified by the American Production & Inventory Control Society (in Production & Inventory Management). He is the co-author of Production and Management Systems for Business, published by Prentice Hall and is the coinventor on six patents. (Evaluator, Cohort #2, Spring 2015)

Olukemi Sawyerr is the inaugural director of the Student Innovation Idea Lab at California State Polytechnic University, Pomona and a full professor in the Department of Management and Human Resources. She co-founded the Entrepreneurship in STEM Education (ESTEME) Program and the CPP Technology Screen Assessment Program in collaboration with NASA Armstrong Flight Research Center (AFRC). Her Ph.D. in Strategic Management is from the University of North Texas. Her work has appeared in journals such as Strategic Management Journal, Journal of Small Business Management, International Small Business Journal, Journal of Applied Management Studies, and Journal of High Technology Management Research. (Evaluator, Cohort #3, Fall 2015)

Lisa Sherman is a Senior Associate Scientist of Amgen, Inc., based in Thousand Oaks. She earned her bachelor’s degree in Microbiology, with a concentration in Applied Microbiology and Biotechnology at Cal Poly San Luis Obispo in 2003. Since then, she has worked at Amgen in the Inflammation Department within Discovery Research. She is experienced in developing in-vitro/ex-vivo experiments to investigate biological and cellular pathways/processes and large- and small-molecule screening for drug discovery research (specifically image-based technologies, cell-based, and biochemical assays). Most recently, her efforts are focusing on utilizing fresh human tissue, diseased and normal, and by replicating disease pathogenesis, assessing important phenotypes and transcriptomics that could lead to novel targets. (Evaluator, Cohort #3, Fall 2015)

Manmeet Singh is a student at CSU Sacramento and a research project manager at Stem Cell Partners LLC.  She participated in the Idea to Product (CSU I-Corps precursor program) as part of the StemPatch team.  Subsequently she participated in the national NSF I-Corps program as an Entrepreneurial Lead. (Teaching Team & Evaluator, Cohort #1, Fall 2014)

Louis Stewart currently serves as the Deputy Director of Innovation and Entrepreneurship in the Governor’s Office of Business and Economic Development (GO-Biz), where he oversees the coordination and promotion of innovative programs, activities, and emerging technologies throughout the state of California. At GO-Biz, Mr. Stewart manages a robust statewide innovation-based economic development support network of regional innovation clusters called the California Innovation Hubs (iHubs). The 16 iHubs were designed to stimulate local, regional, and statewide job creation as well as enhance the awareness, visibility, and opportunities for commercialization of the technologies emerging from GO-Biz’ iHub partners. Mr. Stewart’s role includes a priority to develop an ecosystem that endorses entrepreneurship as well as promotes approaches that will augment strategic business development opportunities. High profile business opportunities are coordinated and managed in order to retain and expand business investment, assist in job creation, and enhance economic opportunities through collaboration and innovation. Mr. Stewart comes from the private sector where he has 17 years of experience in Sales, Marketing, and Information Technologies. He received his Bachelor of Arts degree from Santa Clara University. (Evaluator, Cohort #3, Fall 2015)

Marie Talnack is Director of Technology Transfer Office and Industry Clinic, California State Polytechnic University, Pomona. Marie Talnack has worked in both public programs and private industry. Her major interest is in the transfer of technologies from publicly funded research to small businesses in order to commercialize technology, thus creating new business opportunities. Dr. Talnack’s career in Technology Transfer and Business Development has spanned over 25 years as a Technology Transfer and Commercialization Specialist. She holds a Doctorate in Science and Technology Policy from the University of Southern California, MBA in Finance and Marketing, and Masters in International Management. Her professional career in technology transfer includes four research universities and two national research laboratories as well as her own consulting firm established in 1991. Dr. Talnack is committed to university/industry collaborations and was a co-author of the National Academies’ recent publication, The Researcher’s Guidebook. (Teaching Team & Evaluator, Cohort #3, Fall 2015; Teaching Team, Cohort #5, Fall 2016)

Sandra Thompson has spent the last 16 years counseling domestic and international clients of all sizes—from Fortune 50 to startups to universities—on patent, trademark, copyright and new media transactional matters. She represents clients in the fields of green technology and chemistry, semiconductors, medical devices, high resolution audio software and hardware, chemicals and chemical intermediates, solar and solar-related technology, transportation technology, bio-based and biodegradable plastics, pharmaceuticals and telecommunications. Dr. Thompson earned her J.D. at Campbell University and her B.S. and M.A. at the College of William & Mary. She earned her PhD from the Department of Chemistry at North Carolina State University. As a doctoral candidate, Dr. Thompson worked at both the Environmental Protection Agency and the Research Triangle Institute in Research Triangle Park, North Carolina.  (Evaluator, Cohort #1, Fall 2014; Teaching Team, Cohort #2, Spring 2015; Evaluator, Cohort #3, Fall 2015)

Christina Waters is CEO/Founder of RARE Science, a non-profit research organization focusing on accelerating cures for kids with rare disease. She serves as a Scientific Advisory board member for Global Genes and a Senior Advisor for Personalized Medicine for Pricewaterhouse Coopers. Dr. Waters received her PhD in Genetics from UC Davis. She was a Postdoctoral Scholar of the Howard Hughes Medical Institute, California Institute of Technology, a NIH Postdoctoral fellowship at UC Berkeley, received a BS from SDSU and a MBA from UC Los Angeles. She was awarded SDSU College of Sciences Award for Outstanding Alumni in 2010. (Evaluator, Cohort #3, Fall 2015)